maraviroc + atorvastatin
Phase 3- Indications
- Long COVID, Post-Acute Sequelae of COVID-19
Company intelligence / Profile preview
HealthBio has developed a proprietary diagnostic and therapeutic platform targeting the root cause of chronic inflammation in conditions like Long COVID. Their patented combination therapy with maraviroc and atorvastatin addresses persistent immune activation via the CCR5 pathway. Pre-trial data reportedly show strong statistical significance in symptom improvement. The company received FDA approval to begin a double-blind placebo-controlled Phase 2 trial in January 2024; patient enrollment began March 2025. Over 12,000 patients have been treated under protocol since inception with promising results reported anecdotally/preliminarily.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HealthBio.